-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HiCIuY2xyY2c8qhlyxdUdJggBlCx5KjfvavZnJXVG2+yaQTq5ZVHv2Jfd3/M5vL0 HWCbhp7O1GCOE8IcMHdFbQ== 0001209191-08-067583.txt : 20081229 0001209191-08-067583.hdr.sgml : 20081225 20081229180127 ACCESSION NUMBER: 0001209191-08-067583 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20081223 FILED AS OF DATE: 20081229 DATE AS OF CHANGE: 20081229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KILLION FREDERICK CENTRAL INDEX KEY: 0001237261 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09860 FILM NUMBER: 081273734 BUSINESS ADDRESS: STREET 1: BARR LABORATORIES INC STREET 2: 300 CORPORATE DRIVE SUITE 10 CITY: BLAUVELT STATE: NY ZIP: 10913 BUSINESS PHONE: 18002275227 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BARR PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000010081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221927534 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 SUMMIT AVE CITY: MONTVALE STATE: NJ ZIP: 07645-1523 BUSINESS PHONE: 201-930-3300 MAIL ADDRESS: STREET 1: 225 SUMMIT AVE CITY: MONTVALE STATE: NJ ZIP: 07645-1523 FORMER COMPANY: FORMER CONFORMED NAME: BARR LABORATORIES INC DATE OF NAME CHANGE: 19920703 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2008-12-23 1 0000010081 BARR PHARMACEUTICALS INC BRL 0001237261 KILLION FREDERICK BARR PHARMACEUTICALS, INC. 225 SUMMIT AVENUE MONTVALE NJ 07645 0 1 0 0 General Counsel Common Stock 2008-12-23 4 D 0 11589 D 0 D Stock Options 30.1867 2008-12-23 4 D 0 62500 D 2012-03-01 Common Stock 62500 0 D Stock Options 43.34 2008-12-23 4 D 0 45000 D 2013-07-30 Common Stock 45000 0 D Stock Options 35.01 2008-12-23 4 D 0 30000 D 2014-08-04 Common Stock 30000 0 D Stock Appreciation Rights 46.99 2008-12-23 4 D 0 30000 D 2015-07-27 Common Stock 30000 0 D Stock Appreciation Rights 48.80 2008-12-23 4 D 0 30000 D 2008-11-11 2016-07-26 Common Stock 30000 0 D Stock Appreciation Rights 49.49 2008-12-23 4 D 0 15000 D 2008-11-11 2017-03-07 Common Stock 15000 0 D Stock Appreciation Rights 55.81 2008-12-23 4 D 0 30000 D 2008-11-11 2017-08-09 Common Stock 30000 0 D Stock Appreciation Rights 49.22 2008-12-23 4 D 0 45000 D 2008-11-11 2018-03-04 Common Stock 45000 0 D Disposed of pursuant to a merger agreement between Issuer and Teva Pharmaceutical Industries Ltd. in exchange for 7,268 shares of Teva Common Stock having a market value of $41.82 per share on the effective date of the merger and cash in the amount of $462,401.10. Option vested equally over a 3 year period from grant date These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $2,269,581.25, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $30.1867 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $1,042,200, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $43.34 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $944,700, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $35.01 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $585,300, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $46.99 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $531,000, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $48.80 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $255,150, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.49 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $320,700, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $55.81 per share. These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $777,600, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.22 per share. /s/ William T. McKee as Attorney-in-Fact for Frederick Killion 2008-12-29 -----END PRIVACY-ENHANCED MESSAGE-----